troglitazone has been researched along with Thyroid Neoplasms in 7 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cotreatment with troglitazone and lovastatin altered the epithelial-to-mesenchymal-transition (EMT) -related marker gene expression of the cells; specifically, E-cadherin expression increased and vimentin expression decreased." | 1.42 | Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells. ( Chin, LH; Hsu, SP; Liang, YC; Zhong, WB, 2015) |
| "Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARgamma) that is a ligand-activated transcription factor regulating cell differentiation and growth." | 1.33 | Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. ( Clark, OH; Cotter, P; Duh, QY; Ginzinger, DG; Hyun, WC; Kanauchi, H; Lobo, M; Park, JW; Wong, MG; Zarnegar, R, 2005) |
| " RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel." | 1.33 | Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. ( Copland, JA; Fujiwara, K; Haugen, BR; Klopper, JP; Kreinest, PA; Kurakata, S; Marlow, LA; Smallridge, RC; Williams, SF; Wong, AK, 2006) |
| "We used six thyroid cancer cell lines: TPC-1, FTC-133, FTC-236, FTC-238, XTC-1, and ARO82-1." | 1.32 | Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines. ( Clark, OH; Duh, QY; Hyun, WC; Lobo, M; Park, JW; Wong, MG, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fröhlich, E | 2 |
| Wahl, R | 2 |
| Chin, LH | 1 |
| Hsu, SP | 1 |
| Zhong, WB | 1 |
| Liang, YC | 1 |
| Park, JW | 2 |
| Wong, MG | 2 |
| Lobo, M | 2 |
| Hyun, WC | 2 |
| Duh, QY | 2 |
| Clark, OH | 2 |
| Zarnegar, R | 1 |
| Kanauchi, H | 1 |
| Ginzinger, DG | 1 |
| Cotter, P | 1 |
| Machicao, F | 1 |
| Copland, JA | 1 |
| Marlow, LA | 1 |
| Kurakata, S | 1 |
| Fujiwara, K | 1 |
| Wong, AK | 1 |
| Kreinest, PA | 1 |
| Williams, SF | 1 |
| Haugen, BR | 1 |
| Klopper, JP | 1 |
| Smallridge, RC | 1 |
| Ohta, K | 1 |
| Endo, T | 1 |
| Haraguchi, K | 1 |
| Hershman, JM | 1 |
| Onaya, T | 1 |
1 review available for troglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromans; Female; Forecasting; Gene Expression Regulation, Ne | 2014 |
6 other studies available for troglitazone and Thyroid Neoplasms
| Article | Year |
|---|---|
Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.
Topics: Cell Line, Tumor; Cell Movement; Chromans; Cyclic AMP Response Element-Binding Protein; Cysteine-Ric | 2015 |
Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; | 2003 |
Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
Topics: Adenocarcinoma, Follicular; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Chrom | 2005 |
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transfo | 2005 |
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2006 |
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma, Papillary; Cell Division; | 2001 |